MXRA5_HUMAN
ID MXRA5_HUMAN Reviewed; 2828 AA.
AC Q9NR99; Q6P1M7; Q9Y3Y8;
DT 31-OCT-2006, integrated into UniProtKB/Swiss-Prot.
DT 11-JAN-2011, sequence version 3.
DT 03-AUG-2022, entry version 158.
DE RecName: Full=Matrix-remodeling-associated protein 5;
DE AltName: Full=Adhesion protein with leucine-rich repeats and immunoglobulin domains related to perlecan;
DE Short=Adlican;
DE Flags: Precursor;
GN Name=MXRA5;
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE [MRNA], AND VARIANTS VAL-824; VAL-1128; ASP-1394;
RP SER-2000 AND VAL-2531.
RC TISSUE=Placenta;
RA Crowl R.M., Luk D.;
RT "Identification of the gene encoding adlican, a novel protein expressed in
RT human arthritic tissues.";
RL Submitted (MAR-2000) to the EMBL/GenBank/DDBJ databases.
RN [2]
RP NUCLEOTIDE SEQUENCE [MRNA], AND DEVELOPMENTAL STAGE.
RX PubMed=15609104; DOI=10.1007/s10522-004-3188-1;
RA Chondrogianni N., Simoes D.C.M., Franceschi C., Gonos E.S.;
RT "Cloning of differentially expressed genes in skin fibroblasts from
RT centenarians.";
RL Biogerontology 5:401-409(2004).
RN [3]
RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX PubMed=15772651; DOI=10.1038/nature03440;
RA Ross M.T., Grafham D.V., Coffey A.J., Scherer S., McLay K., Muzny D.,
RA Platzer M., Howell G.R., Burrows C., Bird C.P., Frankish A., Lovell F.L.,
RA Howe K.L., Ashurst J.L., Fulton R.S., Sudbrak R., Wen G., Jones M.C.,
RA Hurles M.E., Andrews T.D., Scott C.E., Searle S., Ramser J., Whittaker A.,
RA Deadman R., Carter N.P., Hunt S.E., Chen R., Cree A., Gunaratne P.,
RA Havlak P., Hodgson A., Metzker M.L., Richards S., Scott G., Steffen D.,
RA Sodergren E., Wheeler D.A., Worley K.C., Ainscough R., Ambrose K.D.,
RA Ansari-Lari M.A., Aradhya S., Ashwell R.I., Babbage A.K., Bagguley C.L.,
RA Ballabio A., Banerjee R., Barker G.E., Barlow K.F., Barrett I.P.,
RA Bates K.N., Beare D.M., Beasley H., Beasley O., Beck A., Bethel G.,
RA Blechschmidt K., Brady N., Bray-Allen S., Bridgeman A.M., Brown A.J.,
RA Brown M.J., Bonnin D., Bruford E.A., Buhay C., Burch P., Burford D.,
RA Burgess J., Burrill W., Burton J., Bye J.M., Carder C., Carrel L.,
RA Chako J., Chapman J.C., Chavez D., Chen E., Chen G., Chen Y., Chen Z.,
RA Chinault C., Ciccodicola A., Clark S.Y., Clarke G., Clee C.M., Clegg S.,
RA Clerc-Blankenburg K., Clifford K., Cobley V., Cole C.G., Conquer J.S.,
RA Corby N., Connor R.E., David R., Davies J., Davis C., Davis J., Delgado O.,
RA Deshazo D., Dhami P., Ding Y., Dinh H., Dodsworth S., Draper H.,
RA Dugan-Rocha S., Dunham A., Dunn M., Durbin K.J., Dutta I., Eades T.,
RA Ellwood M., Emery-Cohen A., Errington H., Evans K.L., Faulkner L.,
RA Francis F., Frankland J., Fraser A.E., Galgoczy P., Gilbert J., Gill R.,
RA Gloeckner G., Gregory S.G., Gribble S., Griffiths C., Grocock R., Gu Y.,
RA Gwilliam R., Hamilton C., Hart E.A., Hawes A., Heath P.D., Heitmann K.,
RA Hennig S., Hernandez J., Hinzmann B., Ho S., Hoffs M., Howden P.J.,
RA Huckle E.J., Hume J., Hunt P.J., Hunt A.R., Isherwood J., Jacob L.,
RA Johnson D., Jones S., de Jong P.J., Joseph S.S., Keenan S., Kelly S.,
RA Kershaw J.K., Khan Z., Kioschis P., Klages S., Knights A.J., Kosiura A.,
RA Kovar-Smith C., Laird G.K., Langford C., Lawlor S., Leversha M., Lewis L.,
RA Liu W., Lloyd C., Lloyd D.M., Loulseged H., Loveland J.E., Lovell J.D.,
RA Lozado R., Lu J., Lyne R., Ma J., Maheshwari M., Matthews L.H.,
RA McDowall J., McLaren S., McMurray A., Meidl P., Meitinger T., Milne S.,
RA Miner G., Mistry S.L., Morgan M., Morris S., Mueller I., Mullikin J.C.,
RA Nguyen N., Nordsiek G., Nyakatura G., O'dell C.N., Okwuonu G., Palmer S.,
RA Pandian R., Parker D., Parrish J., Pasternak S., Patel D., Pearce A.V.,
RA Pearson D.M., Pelan S.E., Perez L., Porter K.M., Ramsey Y., Reichwald K.,
RA Rhodes S., Ridler K.A., Schlessinger D., Schueler M.G., Sehra H.K.,
RA Shaw-Smith C., Shen H., Sheridan E.M., Shownkeen R., Skuce C.D.,
RA Smith M.L., Sotheran E.C., Steingruber H.E., Steward C.A., Storey R.,
RA Swann R.M., Swarbreck D., Tabor P.E., Taudien S., Taylor T., Teague B.,
RA Thomas K., Thorpe A., Timms K., Tracey A., Trevanion S., Tromans A.C.,
RA d'Urso M., Verduzco D., Villasana D., Waldron L., Wall M., Wang Q.,
RA Warren J., Warry G.L., Wei X., West A., Whitehead S.L., Whiteley M.N.,
RA Wilkinson J.E., Willey D.L., Williams G., Williams L., Williamson A.,
RA Williamson H., Wilming L., Woodmansey R.L., Wray P.W., Yen J., Zhang J.,
RA Zhou J., Zoghbi H., Zorilla S., Buck D., Reinhardt R., Poustka A.,
RA Rosenthal A., Lehrach H., Meindl A., Minx P.J., Hillier L.W., Willard H.F.,
RA Wilson R.K., Waterston R.H., Rice C.M., Vaudin M., Coulson A., Nelson D.L.,
RA Weinstock G., Sulston J.E., Durbin R.M., Hubbard T., Gibbs R.A., Beck S.,
RA Rogers J., Bentley D.R.;
RT "The DNA sequence of the human X chromosome.";
RL Nature 434:325-337(2005).
RN [4]
RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 1-739.
RC TISSUE=Muscle;
RX PubMed=15489334; DOI=10.1101/gr.2596504;
RG The MGC Project Team;
RT "The status, quality, and expansion of the NIH full-length cDNA project:
RT the Mammalian Gene Collection (MGC).";
RL Genome Res. 14:2121-2127(2004).
RN [5]
RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 2245-2828.
RC TISSUE=Brain;
RX PubMed=17974005; DOI=10.1186/1471-2164-8-399;
RA Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U.,
RA Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H., Heubner D.,
RA Hoerlein A., Michel G., Wedler H., Koehrer K., Ottenwaelder B., Poustka A.,
RA Wiemann S., Schupp I.;
RT "The full-ORF clone resource of the German cDNA consortium.";
RL BMC Genomics 8:399-399(2007).
RN [6]
RP FUNCTION, INDUCTION BY TGFB1, TISSUE SPECIFICITY, AND SUBCELLULAR LOCATION.
RX PubMed=27599751; DOI=10.1111/jcmm.12953;
RA Poveda J., Sanz A.B., Fernandez-Fernandez B., Carrasco S., Ruiz-Ortega M.,
RA Cannata-Ortiz P., Ortiz A., Sanchez-Nino M.D.;
RT "MXRA5 is a TGF-beta1-regulated human protein with anti-inflammatory and
RT anti-fibrotic properties.";
RL J. Cell. Mol. Med. 21:154-164(2017).
RN [7]
RP VARIANTS LNCR ASP-98; HIS-481; CYS-611; ASN-862; PHE-1028; ALA-1491;
RP HIS-2300; TRP-2349; ARG-2678; ALA-2716 AND GLY-2763.
RX PubMed=22696596; DOI=10.1093/carcin/bgs210;
RA Xiong D., Li G., Li K., Xu Q., Pan Z., Ding F., Vedell P., Liu P., Cui P.,
RA Hua X., Jiang H., Yin Y., Zhu Z., Li X., Zhang B., Ma D., Wang Y., You M.;
RT "Exome sequencing identifies MXRA5 as a novel cancer gene frequently
RT mutated in non-small cell lung carcinoma from Chinese patients.";
RL Carcinogenesis 33:1797-1805(2012).
RN [8]
RP VARIANTS HIS-1163 AND TRP-2663.
RX PubMed=23092983; DOI=10.1038/tp.2012.102;
RA Nava C., Lamari F., Heron D., Mignot C., Rastetter A., Keren B., Cohen D.,
RA Faudet A., Bouteiller D., Gilleron M., Jacquette A., Whalen S., Afenjar A.,
RA Perisse D., Laurent C., Dupuits C., Gautier C., Gerard M., Huguet G.,
RA Caillet S., Leheup B., Leboyer M., Gillberg C., Delorme R., Bourgeron T.,
RA Brice A., Depienne C.;
RT "Analysis of the chromosome X exome in patients with autism spectrum
RT disorders identified novel candidate genes, including TMLHE.";
RL Transl. Psychiatry 2:E179-E179(2012).
RN [9]
RP VARIANT ASP-2426.
RX PubMed=26566883; DOI=10.1136/jmedgenet-2015-103179;
RA Rafiullah R., Aslamkhan M., Paramasivam N., Thiel C., Mustafa G.,
RA Wiemann S., Schlesner M., Wade R.C., Rappold G.A., Berkel S.;
RT "Homozygous missense mutation in the LMAN2L gene segregates with
RT intellectual disability in a large consanguineous Pakistani family.";
RL J. Med. Genet. 53:138-144(2016).
CC -!- FUNCTION: In kidney, has anti-inflammatory and anti-fibrotic properties
CC by limiting the induction of chemokines, fibronectin and collagen
CC expression in response to TGB1 and pro-inflammatory stimuli.
CC {ECO:0000269|PubMed:27599751}.
CC -!- SUBCELLULAR LOCATION: Secreted {ECO:0000269|PubMed:27599751}.
CC -!- TISSUE SPECIFICITY: Highly expressed in kidney, also detected on liver
CC and spleen (PubMed:27599751). Expressed by proximal tubular cells of
CC the kidney (at protein level) (PubMed:27599751). Expression highly
CC increases during chronic kidney disease and autosomal dominant
CC polycystic kidney disease, where is detected in cysts
CC (PubMed:27599751). {ECO:0000269|PubMed:27599751}.
CC -!- DEVELOPMENTAL STAGE: Over-expressed in centenarians. Expression is
CC reduced from young to old but increased from old to centenarians.
CC {ECO:0000269|PubMed:15609104}.
CC -!- INDUCTION: Expression is induced by TGFB1, in kidney tubular cells.
CC This induction is inhibited by the vitamin D receptor activator
CC paricalcitol (at protein level). {ECO:0000269|PubMed:27599751}.
CC -!- DISEASE: Lung cancer (LNCR) [MIM:211980]: A common malignancy affecting
CC tissues of the lung. The most common form of lung cancer is non-small
CC cell lung cancer (NSCLC) that can be divided into 3 major histologic
CC subtypes: squamous cell carcinoma, adenocarcinoma, and large cell lung
CC cancer. NSCLC is often diagnosed at an advanced stage and has a poor
CC prognosis. {ECO:0000269|PubMed:22696596}. Note=Disease susceptibility
CC may be associated with variants affecting the gene represented in this
CC entry.
CC -!- SEQUENCE CAUTION:
CC Sequence=AAH11846.1; Type=Miscellaneous discrepancy; Note=Contaminating sequence. Potential poly-A sequence.; Evidence={ECO:0000305};
CC Sequence=AAH64986.1; Type=Miscellaneous discrepancy; Note=Contaminating sequence. Potential poly-A sequence.; Evidence={ECO:0000305};
CC Sequence=AAH80586.1; Type=Miscellaneous discrepancy; Note=Contaminating sequence. Potential poly-A sequence.; Evidence={ECO:0000305};
CC ---------------------------------------------------------------------------
CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC ---------------------------------------------------------------------------
DR EMBL; AF245505; AAF86402.1; -; mRNA.
DR EMBL; AC004616; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR EMBL; BC011846; AAH11846.1; ALT_SEQ; mRNA.
DR EMBL; BC064986; AAH64986.1; ALT_SEQ; mRNA.
DR EMBL; BC080586; AAH80586.1; ALT_SEQ; mRNA.
DR EMBL; AL049946; CAB43220.1; -; mRNA.
DR CCDS; CCDS14124.1; -.
DR PIR; T08678; T08678.
DR RefSeq; NP_056234.2; NM_015419.3.
DR BioGRID; 117392; 9.
DR IntAct; Q9NR99; 4.
DR STRING; 9606.ENSP00000217939; -.
DR GlyConnect; 1495; 24 N-Linked glycans (7 sites).
DR GlyGen; Q9NR99; 24 sites, 23 N-linked glycans (7 sites), 4 O-linked glycans (13 sites).
DR iPTMnet; Q9NR99; -.
DR PhosphoSitePlus; Q9NR99; -.
DR BioMuta; MXRA5; -.
DR DMDM; 317373412; -.
DR EPD; Q9NR99; -.
DR jPOST; Q9NR99; -.
DR MassIVE; Q9NR99; -.
DR PaxDb; Q9NR99; -.
DR PeptideAtlas; Q9NR99; -.
DR PRIDE; Q9NR99; -.
DR ProteomicsDB; 82314; -.
DR Antibodypedia; 362; 71 antibodies from 22 providers.
DR DNASU; 25878; -.
DR Ensembl; ENST00000217939.7; ENSP00000217939.5; ENSG00000101825.8.
DR GeneID; 25878; -.
DR KEGG; hsa:25878; -.
DR MANE-Select; ENST00000217939.7; ENSP00000217939.5; NM_015419.4; NP_056234.2.
DR UCSC; uc004crg.6; human.
DR CTD; 25878; -.
DR DisGeNET; 25878; -.
DR GeneCards; MXRA5; -.
DR HGNC; HGNC:7539; MXRA5.
DR HPA; ENSG00000101825; Tissue enhanced (cervix).
DR MalaCards; MXRA5; -.
DR MIM; 211980; phenotype.
DR MIM; 300938; gene.
DR neXtProt; NX_Q9NR99; -.
DR OpenTargets; ENSG00000101825; -.
DR PharmGKB; PA31340; -.
DR VEuPathDB; HostDB:ENSG00000101825; -.
DR eggNOG; KOG0619; Eukaryota.
DR GeneTree; ENSGT00940000159942; -.
DR HOGENOM; CLU_000580_0_0_1; -.
DR InParanoid; Q9NR99; -.
DR OMA; MRWFLEW; -.
DR OrthoDB; 8971at2759; -.
DR PhylomeDB; Q9NR99; -.
DR TreeFam; TF326318; -.
DR PathwayCommons; Q9NR99; -.
DR SignaLink; Q9NR99; -.
DR BioGRID-ORCS; 25878; 8 hits in 697 CRISPR screens.
DR ChiTaRS; MXRA5; human.
DR GeneWiki; MXRA5; -.
DR GenomeRNAi; 25878; -.
DR Pharos; Q9NR99; Tbio.
DR PRO; PR:Q9NR99; -.
DR Proteomes; UP000005640; Chromosome X.
DR RNAct; Q9NR99; protein.
DR Bgee; ENSG00000101825; Expressed in tendon of biceps brachii and 173 other tissues.
DR Genevisible; Q9NR99; HS.
DR GO; GO:0062023; C:collagen-containing extracellular matrix; HDA:BHF-UCL.
DR GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB.
DR GO; GO:0005576; C:extracellular region; IBA:GO_Central.
DR GO; GO:0005201; F:extracellular matrix structural constituent; HDA:BHF-UCL.
DR GO; GO:0071559; P:response to transforming growth factor beta; IMP:UniProtKB.
DR Gene3D; 2.60.40.10; -; 12.
DR Gene3D; 3.80.10.10; -; 2.
DR InterPro; IPR000483; Cys-rich_flank_reg_C.
DR InterPro; IPR007110; Ig-like_dom.
DR InterPro; IPR036179; Ig-like_dom_sf.
DR InterPro; IPR013783; Ig-like_fold.
DR InterPro; IPR013098; Ig_I-set.
DR InterPro; IPR003599; Ig_sub.
DR InterPro; IPR003598; Ig_sub2.
DR InterPro; IPR001611; Leu-rich_rpt.
DR InterPro; IPR003591; Leu-rich_rpt_typical-subtyp.
DR InterPro; IPR032675; LRR_dom_sf.
DR InterPro; IPR000372; LRRNT.
DR Pfam; PF07679; I-set; 6.
DR Pfam; PF13855; LRR_8; 1.
DR SMART; SM00409; IG; 12.
DR SMART; SM00408; IGc2; 12.
DR SMART; SM00369; LRR_TYP; 6.
DR SMART; SM00082; LRRCT; 1.
DR SMART; SM00013; LRRNT; 1.
DR SUPFAM; SSF48726; SSF48726; 12.
DR PROSITE; PS50835; IG_LIKE; 12.
PE 1: Evidence at protein level;
KW Disulfide bond; Glycoprotein; Leucine-rich repeat; Reference proteome;
KW Repeat; Secreted; Signal.
FT SIGNAL 1..26
FT /evidence="ECO:0000255"
FT CHAIN 27..2828
FT /note="Matrix-remodeling-associated protein 5"
FT /id="PRO_0000254131"
FT DOMAIN 27..55
FT /note="LRRNT"
FT REPEAT 56..77
FT /note="LRR 1"
FT REPEAT 80..101
FT /note="LRR 2"
FT REPEAT 104..125
FT /note="LRR 3"
FT REPEAT 128..149
FT /note="LRR 4"
FT REPEAT 152..173
FT /note="LRR 5"
FT REPEAT 184..205
FT /note="LRR 6"
FT DOMAIN 217..277
FT /note="LRRCT"
FT DOMAIN 481..571
FT /note="Ig-like C2-type 1"
FT DOMAIN 575..669
FT /note="Ig-like C2-type 2"
FT REPEAT 1410..1434
FT /note="LRR 7"
FT DOMAIN 1853..1946
FT /note="Ig-like C2-type 3"
FT DOMAIN 1950..2041
FT /note="Ig-like C2-type 4"
FT DOMAIN 2046..2140
FT /note="Ig-like C2-type 5"
FT DOMAIN 2146..2239
FT /note="Ig-like C2-type 6"
FT DOMAIN 2242..2343
FT /note="Ig-like C2-type 7"
FT DOMAIN 2345..2432
FT /note="Ig-like C2-type 8"
FT DOMAIN 2440..2534
FT /note="Ig-like C2-type 9"
FT DOMAIN 2542..2630
FT /note="Ig-like C2-type 10"
FT DOMAIN 2637..2722
FT /note="Ig-like C2-type 11"
FT DOMAIN 2733..2828
FT /note="Ig-like C2-type 12"
FT REGION 671..715
FT /note="Disordered"
FT /evidence="ECO:0000256|SAM:MobiDB-lite"
FT REGION 933..962
FT /note="Disordered"
FT /evidence="ECO:0000256|SAM:MobiDB-lite"
FT REGION 1068..1190
FT /note="Disordered"
FT /evidence="ECO:0000256|SAM:MobiDB-lite"
FT REGION 1204..1275
FT /note="Disordered"
FT /evidence="ECO:0000256|SAM:MobiDB-lite"
FT REGION 1367..1389
FT /note="Disordered"
FT /evidence="ECO:0000256|SAM:MobiDB-lite"
FT REGION 1479..1499
FT /note="Disordered"
FT /evidence="ECO:0000256|SAM:MobiDB-lite"
FT REGION 1536..1566
FT /note="Disordered"
FT /evidence="ECO:0000256|SAM:MobiDB-lite"
FT REGION 1579..1603
FT /note="Disordered"
FT /evidence="ECO:0000256|SAM:MobiDB-lite"
FT REGION 1669..1689
FT /note="Disordered"
FT /evidence="ECO:0000256|SAM:MobiDB-lite"
FT REGION 1700..1719
FT /note="Disordered"
FT /evidence="ECO:0000256|SAM:MobiDB-lite"
FT COMPBIAS 686..715
FT /note="Basic and acidic residues"
FT /evidence="ECO:0000256|SAM:MobiDB-lite"
FT COMPBIAS 1087..1112
FT /note="Polar residues"
FT /evidence="ECO:0000256|SAM:MobiDB-lite"
FT COMPBIAS 1119..1147
FT /note="Polar residues"
FT /evidence="ECO:0000256|SAM:MobiDB-lite"
FT COMPBIAS 1148..1168
FT /note="Basic residues"
FT /evidence="ECO:0000256|SAM:MobiDB-lite"
FT COMPBIAS 1170..1190
FT /note="Polar residues"
FT /evidence="ECO:0000256|SAM:MobiDB-lite"
FT COMPBIAS 1204..1219
FT /note="Polar residues"
FT /evidence="ECO:0000256|SAM:MobiDB-lite"
FT COMPBIAS 1242..1275
FT /note="Polar residues"
FT /evidence="ECO:0000256|SAM:MobiDB-lite"
FT COMPBIAS 1374..1389
FT /note="Polar residues"
FT /evidence="ECO:0000256|SAM:MobiDB-lite"
FT COMPBIAS 1538..1566
FT /note="Polar residues"
FT /evidence="ECO:0000256|SAM:MobiDB-lite"
FT CARBOHYD 287
FT /note="N-linked (GlcNAc...) asparagine"
FT /evidence="ECO:0000255"
FT CARBOHYD 321
FT /note="N-linked (GlcNAc...) asparagine"
FT /evidence="ECO:0000255"
FT CARBOHYD 633
FT /note="N-linked (GlcNAc...) asparagine"
FT /evidence="ECO:0000255"
FT CARBOHYD 1403
FT /note="N-linked (GlcNAc...) asparagine"
FT /evidence="ECO:0000255"
FT CARBOHYD 1735
FT /note="N-linked (GlcNAc...) asparagine"
FT /evidence="ECO:0000255"
FT CARBOHYD 2007
FT /note="N-linked (GlcNAc...) asparagine"
FT /evidence="ECO:0000255"
FT CARBOHYD 2056
FT /note="N-linked (GlcNAc...) asparagine"
FT /evidence="ECO:0000255"
FT CARBOHYD 2693
FT /note="N-linked (GlcNAc...) asparagine"
FT /evidence="ECO:0000255"
FT DISULFID 501..555
FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114"
FT DISULFID 599..651
FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114"
FT DISULFID 1875..1928
FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114"
FT DISULFID 1972..2025
FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114"
FT DISULFID 2069..2122
FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114"
FT DISULFID 2168..2221
FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114"
FT DISULFID 2265..2324
FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114"
FT DISULFID 2368..2418
FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114"
FT DISULFID 2466..2518
FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114"
FT DISULFID 2564..2616
FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114"
FT DISULFID 2659..2711
FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114"
FT DISULFID 2755..2810
FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114"
FT VARIANT 98
FT /note="A -> D (in LNCR; unknown pathological significance)"
FT /evidence="ECO:0000269|PubMed:22696596"
FT /id="VAR_072405"
FT VARIANT 481
FT /note="P -> H (in LNCR; unknown pathological significance;
FT dbSNP:rs759222135)"
FT /evidence="ECO:0000269|PubMed:22696596"
FT /id="VAR_072406"
FT VARIANT 611
FT /note="W -> C (in LNCR; unknown pathological significance)"
FT /evidence="ECO:0000269|PubMed:22696596"
FT /id="VAR_072407"
FT VARIANT 764
FT /note="V -> L (in dbSNP:rs5983120)"
FT /id="VAR_056057"
FT VARIANT 824
FT /note="I -> V (in dbSNP:rs5983119)"
FT /evidence="ECO:0000269|Ref.1"
FT /id="VAR_060357"
FT VARIANT 862
FT /note="S -> N (in LNCR)"
FT /evidence="ECO:0000269|PubMed:22696596"
FT /id="VAR_072408"
FT VARIANT 1028
FT /note="V -> F (in LNCR; unknown pathological significance)"
FT /evidence="ECO:0000269|PubMed:22696596"
FT /id="VAR_072409"
FT VARIANT 1128
FT /note="A -> V (in dbSNP:rs1635246)"
FT /evidence="ECO:0000269|Ref.1"
FT /id="VAR_060358"
FT VARIANT 1163
FT /note="R -> H (in dbSNP:rs139106444)"
FT /evidence="ECO:0000269|PubMed:23092983"
FT /id="VAR_076257"
FT VARIANT 1394
FT /note="G -> D (in dbSNP:rs1726199)"
FT /evidence="ECO:0000269|Ref.1"
FT /id="VAR_060359"
FT VARIANT 1484
FT /note="T -> A (in dbSNP:rs12396910)"
FT /id="VAR_056058"
FT VARIANT 1491
FT /note="P -> A (in LNCR; unknown pathological significance;
FT dbSNP:rs754393038)"
FT /evidence="ECO:0000269|PubMed:22696596"
FT /id="VAR_072410"
FT VARIANT 1665
FT /note="P -> S (in dbSNP:rs1974522)"
FT /id="VAR_056059"
FT VARIANT 2000
FT /note="G -> S (in dbSNP:rs1635242)"
FT /evidence="ECO:0000269|Ref.1"
FT /id="VAR_060360"
FT VARIANT 2300
FT /note="R -> H (in LNCR; unknown pathological significance;
FT dbSNP:rs776590689)"
FT /evidence="ECO:0000269|PubMed:22696596"
FT /id="VAR_072411"
FT VARIANT 2349
FT /note="R -> W (in LNCR; unknown pathological significance;
FT dbSNP:rs369042203)"
FT /evidence="ECO:0000269|PubMed:22696596"
FT /id="VAR_072412"
FT VARIANT 2426
FT /note="E -> D (in dbSNP:rs148675322)"
FT /evidence="ECO:0000269|PubMed:26566883"
FT /id="VAR_076437"
FT VARIANT 2531
FT /note="L -> V (in dbSNP:rs1726208)"
FT /evidence="ECO:0000269|Ref.1"
FT /id="VAR_028821"
FT VARIANT 2663
FT /note="G -> W (in dbSNP:rs143264543)"
FT /evidence="ECO:0000269|PubMed:23092983"
FT /id="VAR_076258"
FT VARIANT 2678
FT /note="H -> R (in LNCR; unknown pathological significance)"
FT /evidence="ECO:0000269|PubMed:22696596"
FT /id="VAR_072413"
FT VARIANT 2716
FT /note="E -> A (in LNCR; unknown pathological significance;
FT dbSNP:rs1419255508)"
FT /evidence="ECO:0000269|PubMed:22696596"
FT /id="VAR_072414"
FT VARIANT 2763
FT /note="A -> G (in LNCR; unknown pathological significance)"
FT /evidence="ECO:0000269|PubMed:22696596"
FT /id="VAR_072415"
FT CONFLICT 55
FT /note="K -> R (in Ref. 1; AAF86402)"
FT /evidence="ECO:0000305"
FT CONFLICT 1565
FT /note="Q -> R (in Ref. 1; AAF86402)"
FT /evidence="ECO:0000305"
FT CONFLICT 2245
FT /note="I -> V (in Ref. 5; CAB43220)"
FT /evidence="ECO:0000305"
FT CONFLICT 2353
FT /note="Y -> C (in Ref. 5; CAB43220)"
FT /evidence="ECO:0000305"
FT CONFLICT 2640
FT /note="N -> S (in Ref. 5; CAB43220)"
FT /evidence="ECO:0000305"
SQ SEQUENCE 2828 AA; 312150 MW; 0534732CE87C9A8F CRC64;
MPKRAHWGAL SVVLILLWGH PRVALACPHP CACYVPSEVH CTFRSLASVP AGIAKHVERI
NLGFNSIQAL SETSFAGLTK LELLMIHGNE IPSIPDGALR DLSSLQVFKF SYNKLRVITG
QTLQGLSNLM RLHIDHNKIE FIHPQAFNGL TSLRLLHLEG NLLHQLHPST FSTFTFLDYF
RLSTIRHLYL AENMVRTLPA SMLRNMPLLE NLYLQGNPWT CDCEMRWFLE WDAKSRGILK
CKKDKAYEGG QLCAMCFSPK KLYKHEIHKL KDMTCLKPSI ESPLRQNRSR SIEEEQEQEE
DGGSQLILEK FQLPQWSISL NMTDEHGNMV NLVCDIKKPM DVYKIHLNQT DPPDIDINAT
VALDFECPMT RENYEKLWKL IAYYSEVPVK LHRELMLSKD PRVSYQYRQD ADEEALYYTG
VRAQILAEPE WVMQPSIDIQ LNRRQSTAKK VLLSYYTQYS QTISTKDTRQ ARGRSWVMIE
PSGAVQRDQT VLEGGPCQLS CNVKASESPS IFWVLPDGSI LKAPMDDPDS KFSILSSGWL
RIKSMEPSDS GLYQCIAQVR DEMDRMVYRV LVQSPSTQPA EKDTVTIGKN PGESVTLPCN
ALAIPEAHLS WILPNRRIIN DLANTSHVYM LPNGTLSIPK VQVSDSGYYR CVAVNQQGAD
HFTVGITVTK KGSGLPSKRG RRPGAKALSR VREDIVEDEG GSGMGDEENT SRRLLHPKDQ
EVFLKTKDDA INGDKKAKKG RRKLKLWKHS EKEPETNVAE GRRVFESRRR INMANKQINP
ERWADILAKV RGKNLPKGTE VPPLIKTTSP PSLSLEVTPP FPAISPPSAS PVQTVTSAEE
SSADVPLLGE EEHVLGTISS ASMGLEHNHN GVILVEPEVT STPLEEVVDD LSEKTEEITS
TEGDLKGTAA PTLISEPYEP SPTLHTLDTV YEKPTHEETA TEGWSAADVG SSPEPTSSEY
EPPLDAVSLA ESEPMQYFDP DLETKSQPDE DKMKEDTFAH LTPTPTIWVN DSSTSQLFED
STIGEPGVPG QSHLQGLTDN IHLVKSSLST QDTLLIKKGM KEMSQTLQGG NMLEGDPTHS
RSSESEGQES KSITLPDSTL GIMSSMSPVK KPAETTVGTL LDKDTTTATT TPRQKVAPSS
TMSTHPSRRR PNGRRRLRPN KFRHRHKQTP PTTFAPSETF STQPTQAPDI KISSQVESSL
VPTAWVDNTV NTPKQLEMEK NAEPTSKGTP RRKHGKRPNK HRYTPSTVSS RASGSKPSPS
PENKHRNIVT PSSETILLPR TVSLKTEGPY DSLDYMTTTR KIYSSYPKVQ ETLPVTYKPT
SDGKEIKDDV ATNVDKHKSD ILVTGESITN AIPTSRSLVS TMGEFKEESS PVGFPGTPTW
NPSRTAQPGR LQTGIPVTTS GENLTDPPLL KELEDVDFTS EFLSSLTVST PFHQEEAGSS
TTLSSIKVEV ASSQAETTTL DQDHLETTVA ILLSETRPQN HTPTAARMKE PASSSPSTIL
MSLGQTTTTK PALPSPRISQ ASRDSKENVF LNYVGNPETE ATPVNNEGTQ HMSGPNELST
PSSDQDAFNL STKLELEKQV FGSRSLPRGP DSQRQDGRVH ASHQLTRVPA KPILPTATVR
LPEMSTQSAS RYFVTSQSPR HWTNKPEITT YPSGALPENK QFTTPRLSST TIPLPLHMSK
PSIPSKFTDR RTDQFNGYSK VFGNNNIPEA RNPVGKPPSP RIPHYSNGRL PFFTNKTLSF
PQLGVTRRPQ IPTSPAPVMR ERKVIPGSYN RIHSHSTFHL DFGPPAPPLL HTPQTTGSPS
TNLQNIPMVS STQSSISFIT SSVQSSGSFH QSSSKFFAGG PPASKFWSLG EKPQILTKSP
QTVSVTAETD TVFPCEATGK PKPFVTWTKV STGALMTPNT RIQRFEVLKN GTLVIRKVQV
QDRGQYMCTA SNLHGLDRMV VLLSVTVQQP QILASHYQDV TVYLGDTIAM ECLAKGTPAP
QISWIFPDRR VWQTVSPVEG RITLHENRTL SIKEASFSDR GVYKCVASNA AGADSLAIRL
HVAALPPVIH QEKLENISLP PGLSIHIHCT AKAAPLPSVR WVLGDGTQIR PSQFLHGNLF
VFPNGTLYIR NLAPKDSGRY ECVAANLVGS ARRTVQLNVQ RAAANARITG TSPRRTDVRY
GGTLKLDCSA SGDPWPRILW RLPSKRMIDA LFSFDSRIKV FANGTLVVKS VTDKDAGDYL
CVARNKVGDD YVVLKVDVVM KPAKIEHKEE NDHKVFYGGD LKVDCVATGL PNPEISWSLP
DGSLVNSFMQ SDDSGGRTKR YVVFNNGTLY FNEVGMREEG DYTCFAENQV GKDEMRVRVK
VVTAPATIRN KTYLAVQVPY GDVVTVACEA KGEPMPKVTW LSPTNKVIPT SSEKYQIYQD
GTLLIQKAQR SDSGNYTCLV RNSAGEDRKT VWIHVNVQPP KINGNPNPIT TVREIAAGGS
RKLIDCKAEG IPTPRVLWAF PEGVVLPAPY YGNRITVHGN GSLDIRSLRK SDSVQLVCMA
RNEGGEARLI LQLTVLEPME KPIFHDPISE KITAMAGHTI SLNCSAAGTP TPSLVWVLPN
GTDLQSGQQL QRFYHKADGM LHISGLSSVD AGAYRCVARN AAGHTERLVS LKVGLKPEAN
KQYHNLVSII NGETLKLPCT PPGAGQGRFS WTLPNGMHLE GPQTLGRVSL LDNGTLTVRE
ASVFDRGTYV CRMETEYGPS VTSIPVIVIA YPPRITSEPT PVIYTRPGNT VKLNCMAMGI
PKADITWELP DKSHLKAGVQ ARLYGNRFLH PQGSLTIQHA TQRDAGFYKC MAKNILGSDS
KTTYIHVF
